Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate.

Zhang Y, Panfen E, Fancher M, Sinz M, Marathe P, Shen H.

Mol Pharm. 2019 Jun 3;16(6):2342-2353. doi: 10.1021/acs.molpharmaceut.8b01226. Epub 2019 May 13.

PMID:
31039308
2.

Bioidentical hormones: an evidence-based review for primary care providers.

Conaway E.

J Am Osteopath Assoc. 2011 Mar;111(3):153-64. Review.

PMID:
21464264
3.

Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.

Gui C, Obaidat A, Chaguturu R, Hagenbuch B.

Curr Chem Genomics. 2010 Mar 1;4:1-8. doi: 10.2174/1875397301004010001.

4.

Differences in brain volumes among males and female hormone-therapy users and nonusers.

Greenberg DL, Payne ME, MacFall JR, Provenzale JM, Steffens DC, Krishnan RR.

Psychiatry Res. 2006 Oct 30;147(2-3):127-34. Epub 2006 Aug 28.

PMID:
16935478
5.

Hormone replacement therapy and cognition in an Australian representative sample aged 60-64 years.

Low LF, Anstey KJ, Jorm AF, Christensen H, Rodgers B.

Maturitas. 2006 Apr 20;54(1):86-94. Epub 2005 Oct 12.

PMID:
16226000
6.

Estrogen regulation of the cytochrome P450 3A subfamily in humans.

Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW.

J Pharmacol Exp Ther. 2004 Nov;311(2):728-35. Epub 2004 Jul 28.

PMID:
15282264
7.

Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition.

Muller ME, Webber CE, Adachi JD.

Can J Physiol Pharmacol. 2003 Oct;81(10):952-8.

PMID:
14608412
8.

Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.

Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S.

J Pharmacol Exp Ther. 2003 Dec;307(3):878-87. Epub 2003 Oct 13.

PMID:
14557374
9.

A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.

Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K.

Calcif Tissue Int. 2003 Jul;73(1):33-43.

PMID:
14506952
10.

Estrogen replacement therapy in breast cancer survivors: a matched-controlled series.

Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH.

Menopause. 2003 Jul-Aug;10(4):277-85.

PMID:
12851510
11.

Duramed Pharmaceuticals targets women's health.

[No authors listed]

Contracept Technol Update. 2000 Feb;21(2):19-21.

PMID:
12295619
12.

Estrogen replacement therapy after breast cancer: a 12-year follow-up.

Peters GN, Fodera T, Sabol J, Jones S, Euhus D.

Ann Surg Oncol. 2001 Dec;8(10):828-32.

PMID:
11776498
14.

Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium.

Byrjalsen I, Alexandersen P, Christiansen C.

BJOG. 2000 Mar;107(3):347-55.

16.

Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy.

Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB.

Psychoneuroendocrinology. 1997 Oct;22(7):549-58.

PMID:
9373888
17.

The effect of hormone replacement therapy on vitamin E status in postmenopausal women.

Wen Y, Doyle MC, Harrison RF, Feely J.

Maturitas. 1997 Mar;26(2):121-4.

PMID:
9089561
18.

Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women.

Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB.

Psychoneuroendocrinology. 1996 Oct;21(7):575-92.

PMID:
9044441
20.

Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992.

Wysowski DK, Golden L, Burke L.

Obstet Gynecol. 1995 Jan;85(1):6-10.

PMID:
7800326

Supplemental Content

Loading ...
Support Center